NCT03048747 - A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 2, 2017

Primary Completion Date

March 19, 2019

Study Completion Date

March 19, 2019

Conditions

Syndrome of Inappropriate Antidiuretic Hormone Secretion

Interventions

DRUG

Tolvaptan Oral Tablet

Tolvaptan tablets at 7.5, 15, 30 (one tablet each), or 60 mg (two 30 mg tablets) will be orally administered once daily after breakfast for up to 30 days.

Trial Locations (6)

Unknown

Chubu Region

Chugoku Region

Kanto Region

Kinki Region

Kyushu Region

Sikoku Region